Myeloma Paper of the Day, August 5th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Real-world study of 100 consecutive newly diagnosed AL amyloidosis patients who got upfront daratumumab-based therapy finds approximately 1/3 required second line of treatment within two years predicted by hi BMPCs (Bone Marrow Plasma Cells) and dFLC (Difference in Free Light Chains) at diagnosis: promising responses with venetoclax in t(11;14).”
Source: Robert Orlowski/X
Authors: Abdul-Hamid Bazarbachi, Divaya Bhutani, Jai Radhakrishnan, Markus Mapara, Mathew S. Maurer, Suzanne Lentzsch and Rajshekhar Chakraborty.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
